Announced details
AI analysis of pressure-ulcer images, support for pressure-ulcer assessment by healthcare professionals, and medical applications including the diagnosis, treatment and prevention of disease
A three-party collaboration with Tottori University and 株式会社マイクロン under a basic agreement executed in December 2025. A pre-development consultation was held with PMDA in June 2026.
National University Corporation Tottori University (所在地: Tottori, Tottori Prefecture; President: Harada Satoru (原田省)), 株式会社マイクロン (head office: Minato-ku, Tokyo; Representative Director and President: Suzuki Hiromasa (鈴木宏昌)), and the Pharmaceuticals and Medical Devices Agency (PMDA). Other details: Not disclosed.
Class II Medical Device Marketing Business License
Software as a medical device (SaMD) is positioned as a medium- to long-term growth area for the Medical AI business. The specific amount of the impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
General Incorporated Association Japanese Society of Pressure Ulcers
Ministry of Health, Labour and Welfare and Ministry of Economy, Trade and Industry, “DASH for SaMD 2: Package Strategy 2 to Promote the Practical Application of Software as a Medical Device”
| Item | Details |
|---|---|
| Names of Products / Services Covered | AI for pressure-ulcer care, Software as a medical device (SaMD) |
| Counterparty | National University Corporation Tottori University, 株式会社マイクロン, Pharmaceuticals and Medical Devices Agency (PMDA) |
| Counterparty overview | National University Corporation Tottori University (所在地: Tottori, Tottori Prefecture; President: Harada Satoru (原田省)), 株式会社マイクロン (head office: Minato-ku, Tokyo; Representative Director and President: Suzuki Hiromasa (鈴木宏昌)), and the Pharmaceuticals and Medical Devices Agency (PMDA). Other details: Not disclosed. |
| Relationship with the Company | A three-party collaboration with Tottori University and 株式会社マイクロン under a basic agreement executed in December 2025. A pre-development consultation was held with PMDA in June 2026. |
| Contract Date | December 2025 (basic agreement with Tottori University and 株式会社マイクロン) |
| Applicable area | AI analysis of pressure-ulcer images, support for pressure-ulcer assessment by healthcare professionals, and medical applications including the diagnosis, treatment and prevention of disease |
| Award/certification name | Class II Medical Device Marketing Business License |
| Impact on Business Performance | Software as a medical device (SaMD) is positioned as a medium- to long-term growth area for the Medical AI business. The specific amount of the impact on financial results is Not disclosed. |
| Source | General Incorporated Association Japanese Society of Pressure Ulcers, Ministry of Health, Labour and Welfare and Ministry of Economy, Trade and Industry, “DASH for SaMD 2: Package Strategy 2 to Promote the Practical Application of Software as a Medical Device” |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To advance its Medical AI business, address challenges and needs in clinical settings, and build the organizational foundation for commercialization by leveraging the technical capabilities it has developed through AI and systems development.